[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620473":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":24,"responsibleParty":65,"collaborators":10,"id":67,"slug":10,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with ATTR-CM",null,"Patients with ATTR-CM.",[13],{"name":14,"affiliation":5,"role":15},"Medical Director","STUDY_DIRECTOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":18,"role":19,"phone":23,"phoneExt":10,"email":21},"1-877-256-9526",[25,38,47,56],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Clinical Trial Site","RECRUITING","Naples","Florida","34102","United States",{"type":33,"coordinates":34},"Point",[35,36],-81.79596,26.14234,{"lat":36,"lon":35},{"facility":26,"status":27,"city":39,"state":40,"zip":41,"country":31,"cosmosGeoPoint":42,"geoPoint":46,"contacts":10},"Boston","Massachusetts","02215",{"type":33,"coordinates":43},[44,45],-71.05977,42.35843,{"lat":45,"lon":44},{"facility":26,"status":27,"city":48,"state":49,"zip":50,"country":31,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"New Brunswick","New Jersey","08901",{"type":33,"coordinates":52},[53,54],-74.45182,40.48622,{"lat":54,"lon":53},{"facility":26,"status":27,"city":57,"state":58,"zip":59,"country":31,"cosmosGeoPoint":60,"geoPoint":64,"contacts":10},"Memphis","Tennessee","38120",{"type":33,"coordinates":61},[62,63],-90.04898,35.14953,{"lat":63,"lon":62},{"type":66,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100620473",false,"NCT07358078","DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting","DemonsTTRate","Inclusion Criteria:\n\n* Has a diagnosis of ATTR-CM\n* Is initiating treatment with vutrisiran or another approved ATTR-CM therapy\n\nExclusion Criteria:\n\n* Is enrolled in an interventional clinical trial","ALL","18 Years",{"count":77,"type":78},2000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to:\n\n* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care\n* Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care\n* Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care\n* Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care",[82],"Transthyretin Amyloidosis With Cardiomyopathy",[84,85,86,87,88],"ATTR-CM","Transthyretin","Amyloidosis","ATTR","Cardiomyopathy","2026-04-23",{"date":91,"type":92},"2026-04-24","ACTUAL",{"date":94,"type":92},"2026-01-09",{"date":96,"type":78},"2030-10-23",{"name":5,"class":6},4]